221 related articles for article (PubMed ID: 35878398)
1. Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors.
Ramkissoon SH; Fernandes H; Lopez-Terrada DH; Hameed MR; Trembath DG; Bridge JA; Lindeman NI; Souers RJ; Vasalos P; Brat DJ; Moncur JT
Arch Pathol Lab Med; 2022 May; 147(5):518-524. PubMed ID: 35878398
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract][Full Text] [Related]
3. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
4. 2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review.
Thomas DL
Chin Clin Oncol; 2023 Feb; 12(1):7. PubMed ID: 36922356
[TBL] [Abstract][Full Text] [Related]
5. The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.
Perez A; Huse JT
Curr Neurol Neurosci Rep; 2021 Nov; 21(12):67. PubMed ID: 34817712
[TBL] [Abstract][Full Text] [Related]
6. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Weller M; Reifenberger G
Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
[TBL] [Abstract][Full Text] [Related]
7. 2021 World Health Organization Classification of Brain Tumors.
Meredith DM; Pisapia DJ
Continuum (Minneap Minn); 2023 Dec; 29(6):1638-1661. PubMed ID: 38085892
[TBL] [Abstract][Full Text] [Related]
8. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
9. WES data from 286 diffuse gliomas under the 2021 WHO Classification of Tumors of the Central Nervous System.
Zhao Z; Zhang KN; Sun Z; Yang C; Wang Q; Li G; Wang Z; Zeng F; Chai R; Qian Z; Wang Z; Liu Y; Ma W; Wu F; Jiang T
Sci Data; 2022 Nov; 9(1):692. PubMed ID: 36369198
[TBL] [Abstract][Full Text] [Related]
10. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC
Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485
[TBL] [Abstract][Full Text] [Related]
11. WHO CNS5 2021 classification of gliomas: a practical review and road signs for diagnosing pathologists and proper patho-clinical and neuro-oncological cooperation.
Sejda A; Grajkowska W; Trubicka J; Szutowicz E; Wojdacz T; Kloc W; Iżycka-Świeszewska E
Folia Neuropathol; 2022; 60(2):137-152. PubMed ID: 35950467
[TBL] [Abstract][Full Text] [Related]
12. Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.
Wood MD; Halfpenny AM; Moore SR
Diagn Pathol; 2019 Apr; 14(1):29. PubMed ID: 30967140
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and Predictive Biomarkers in Gliomas.
Śledzińska P; Bebyn MG; Furtak J; Kowalewski J; Lewandowska MA
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638714
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
15. The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2-Summary of Imaging Findings on Pediatric-Type Diffuse High-Grade Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Circumscribed Astrocytic Gliomas.
Park YW; Vollmuth P; Foltyn-Dumitru M; Sahm F; Ahn SS; Chang JH; Kim SH
J Magn Reson Imaging; 2023 Sep; 58(3):690-708. PubMed ID: 37069764
[TBL] [Abstract][Full Text] [Related]
16. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
17. [World Health Organization Classification of Central Nervous System Tumours, 5
Ichimura K
No Shinkei Geka; 2023 Mar; 51(2):349-363. PubMed ID: 37055056
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system.
Gritsch S; Batchelor TT; Gonzalez Castro LN
Cancer; 2022 Jan; 128(1):47-58. PubMed ID: 34633681
[TBL] [Abstract][Full Text] [Related]
19. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
[TBL] [Abstract][Full Text] [Related]
20. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
Malzkorn B; Reifenberger G
Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
